(Q36495397)

14 August 2017

1 reference

title

Parkinson's disease: management (English)

1 reference

14 August 2017

1 reference

C. G. Clough

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1674305

26 October 2022

language of work or name

English

0 references

publication date

1 June 1991

1 reference

full work available at URL

14 August 2017

number of pages

4

1 reference

based on heuristic

inferred from page(s)

https://api.elsevier.com/content/article/PII:014067369192990J?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

https://api.elsevier.com/content/article/PII:014067369192990J?httpAccept=text/plain

26 October 2022

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

26 October 2022

1 reference

14 August 2017

volume

337

1 reference

14 August 2017

issue

8753

1 reference

14 August 2017

page(s)

1324-1327

1 reference

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

14 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Treatment of Parkinsonism With Levodopa

26 October 2022

2

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Parkinson's disease: disability, review, and management

26 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Dementia in idiopathic Parkinson's disease: prevalence and relationship with symptoms and signs of parkinsonism.

26 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia).

26 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Sexual function in patients with Parkinson's disease and their partners

26 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes

26 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

The pre-morbid personality of patients with Parkinson's disease

26 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Cognitive change following MPTP exposure.

26 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Olfactory dysfunction in parkinsonism: A general deficit unrelated to neurologic signs, disease stage, or disease duration

26 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Mitochondrial complex I deficiency in Parkinson's disease

26 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Xenobiotic metabolism in Parkinson's disease

26 October 2022

16

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Predicting Parkinson's disease

26 October 2022

17

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

26 October 2022

19

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Deprenyl suppresses the oxidant stress associated with increased dopamine turnover

26 October 2022

20

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

26 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Effect of deprenyl on the progression of disability in early Parkinson's disease

26 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia

26 October 2022

23

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

26 October 2022

24

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease

26 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Ropinirole without levodopa in Parkinson's disease

26 October 2022

27

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Apomorphine in Parkinson's disease

26 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Subcutaneous apomorphine in the treatment of Parkinson's disease

26 October 2022

30

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Efficacy of sublingual apomorphine in Parkinson's disease

26 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease.

26 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Adrenal medulla grafts enhance recovery of striatal dopaminergic fibers

26 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine.

26 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up

26 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease

26 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year

26 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Fetal neural graft survival.

26 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Embryos and Parkinson's disease

26 October 2022

39

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease

26 October 2022

41

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)92990-J

26 October 2022

Identifiers

1 reference

14 August 2017

1 reference